Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Declines By 98.2%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 26,452 shares, a decline of 98.2% from the June 30th total of 1,511,367 shares. Based on an average trading volume of 67,658 shares, the short-interest ratio is currently 0.4 days. Currently, 0.2% of the shares of the stock are sold short.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC raised its holdings in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares in the last quarter. Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the 3rd quarter worth approximately $57,000. Renaissance Technologies LLC raised its holdings in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares in the last quarter. HRT Financial LP lifted its position in shares of Enlivex Therapeutics by 719.4% during the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in shares of Enlivex Therapeutics by 44.8% during the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after purchasing an additional 19,132 shares during the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analyst Ratings Changes

ENLV has been the topic of a number of analyst reports. HC Wainwright lifted their target price on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Zacks Research upgraded shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Finally, Wall Street Zen raised shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ ENLV traded down $0.16 during mid-day trading on Friday, reaching $4.20. 106,559 shares of the company’s stock were exchanged, compared to its average volume of 69,542. The firm has a market capitalization of $70.69 million, a price-to-earnings ratio of -0.51 and a beta of 1.52. Enlivex Therapeutics has a 52-week low of $4.08 and a 52-week high of $31.50. The company’s 50-day moving average is $8.85 and its 200-day moving average is $12.74.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.